Corporate Profile


Trade Name     Noile-Immune Biotech, Inc.
Foundation April 16, 2015
Representative Hidenobu Ishizaki, President & CEO
 Headquarters  7-17-2 Ginza, Chuo-ku, Tokyo 104-0061, Japan

The origin of “Noile” 


  • No illness
  • No immunity, No life

Our Strength


Breakthrough Technology of CAR-T Platform for Solid Tumors

The efficacy of CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancy. However, this success is not yet extrapolated to solid tumors. To improve the efficacy of CAR-T cells in solid tumors, we promote the next generation CAR-T platform which is superior to conventional CAR-T cells.
Our breakthrough technology will achieve the desired clinical outcomes.

Partnership with Academic Institutions

We are holding a partnership with the National Cancer Center Japan and Yamaguchi University to improve the accuracy in R&D. Clinical trial-based cooperation with the National Cancer Center Japan that boasts an overwhelming number of cases in the field of cancer treatment will lead to faster clinical trials.

A Team of Globally-Successful Researchers

Our team has extensive experience in cancer immunology and immunotherapy both in Japan and the US.
We will provide truly effective cancer immunotherapy based on the trends around the world.